Document is current
Any future updates will be listed below
-
Authors
Eroglu, Elif https://orcid.org/0000-0003-3952-3178
Yen, Christopher Y. T. https://orcid.org/0000-0001-5999-6306
Tsoi, Yat-Long https://orcid.org/0000-0002-8890-3989
Witman, Nevin https://orcid.org/0000-0002-1109-778X
Elewa, Ahmed
Joven Araus, Alberto https://orcid.org/0000-0002-0926-4665
Wang, Heng https://orcid.org/0000-0002-1727-9226
Szattler, Tamara https://orcid.org/0000-0002-1562-1278
Umeano, Chimezie H.
Sohlmér, Jesper https://orcid.org/0000-0003-2607-7500
Goedel, Alexander https://orcid.org/0000-0002-5980-2257
Simon, András https://orcid.org/0000-0002-1018-1891
Chien, Kenneth R. https://orcid.org/0000-0002-2759-8378
- License Information
-
More Information
Article History
Received: 16 July 2021
Accepted: 21 March 2022
First Online: 12 May 2022
Competing interests
: K.R.C. is a scientific founder and equity holder in Moderna Therapeutics and Procella Therapeutics, and chair of the External Science Panel for AstraZeneca. The remaining authors declare no competing interests.
